Immunic (IMUX) Financials: Revenue & Earnings

IMUX price $8.05 +0.44 +5.83%

Ticker
IMUX
Price
$8.05
Change
+0.44 +5.83%
Market cap ?
$109.88M
P/E ?
-1.54
Forward P/E ?
5.33
Dividend yield ?
0.00%
Beta ?
1.45
Sector
Healthcare
Industry
Biotechnology

Financials

2016201720182019202020212022202320242025
6315.12000000000

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory…

Fair value

IMUX fair value $30.20. Price $8.05. Price is 73% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 353. Growth 8.36%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 1.5). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 13.64M. Net debt -14.80M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare IMUX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-12—-0.93——
2026-08-11-0.80-1.16——
2026-05-13-1.08-0.71——
2026-02-26-1.20-0.90——
2025-11-13-1.30-0.18——
2025-08-07-2.00-1.58——
2025-05-15-2.50-2.50——
2025-04-03-2.50-0.22—6.00K
2024-11-07-2.40-2.20—6.00K
2024-08-08-2.10-0.23—10.00K
2024-05-09-2.50-0.27——
2024-02-22-4.80-0.51——
2023-11-14-5.10-0.55——
2023-08-03-5.40-0.53——
2023-05-11-5.80-0.52——
2023-02-23-16.30-0.82——
2022-11-03-6.90-0.67——
2022-08-04-7.20-0.73——
2022-05-10-7.40-0.81——
2022-02-24-8.04-0.77——
2021-11-04-7.60-8.10——
2021-08-06-8.20-7.20——
2021-05-06-16.30-6.90——
2021-02-26-4.60-5.90——
2020-11-05-7.00-6.10——
2020-08-02-9.00-6.20——
2020-05-08-7.90-9.60——
2020-03-16-5.60-0.76——
2019-11-07-8.20-0.67——
2019-08-08-15.20-0.68——
2019-04-10-88.00———
2019-03-04-56.82———
2018-11-07-11.20-11.20——
2018-08-07-12.00-13.20——
2018-05-08-13.60-13.60——
2018-03-13-14.00-12.40——
2017-10-25-12.00-12.80——
2017-08-03-11.60-14.13——
2017-05-09-15.60-14.60——
2017-03-07-14.80-14.20——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-16Nagel Robert ThorvaldBuy25.37K$10.12256.74K
2026-09-16BVF PARTNERS L P/ILBuy25.37K$10.12256.74K
2026-08-06Ridloff ElenaBuy50.74K$14.54737.76K
2026-08-06Ridloff ElenaOther0——
2026-07-05Skerjanec SimonaBuy25.37K$14.80375.48K
2026-07-05Rudick Richard AlanBuy25.37K$14.80375.48K
2026-07-05PHILLIPS BARCLAY ABuy25.37K$14.80375.48K
2026-07-05Neermann JoergBuy25.37K$14.80375.48K
2026-07-05Congleton JonBuy25.37K$14.80375.48K
2026-06-29Congleton JonBuy50.74K$10.90553.07K
2026-06-29Skerjanec SimonaBuy25.37K$10.90276.53K
2026-06-29Rudick Richard AlanBuy25.37K$10.90276.53K
2026-06-29HOWSON TAMAR DBuy25.37K$10.90276.53K
2026-06-29Neermann JoergBuy25.37K$10.90276.53K
2026-06-29PHILLIPS BARCLAY ABuy25.37K$10.90276.53K
2026-06-29Tardio JasonBuy253.00K$11.602.93M
2026-06-29Whaley GlennBuy120.00K$11.601.39M
2026-06-29Vitt DanielBuy445.00K$11.605.16M
2026-06-29BONNEY MICHAEL WBuy100.00K$12.081.21M
2026-06-01Lundgren ErikOther0——
2026-05-22Lundgren ErikBuy1.00M$13.0513.05M
2026-05-16BONNEY MICHAEL WOther0——
2026-04-24Panzara Michael A.Buy300.00K$8.802.64M
2026-04-24Panzara Michael A.Other0——
2026-03-27Congleton JonOther0——
2026-02-17BVF PARTNERS L P/ILOther0——
2026-02-17BVF PARTNERS L P/ILOther0——
2026-02-17BVF PARTNERS L P/ILOther0——
2026-02-17BVF PARTNERS L P/ILOther3.20M——
2026-02-17BVF PARTNERS L P/ILOther3.20M——
2026-02-17Nagel Robert ThorvaldOther0——
2025-07-16Whaley GlennBuy560.00K$0.77431.20K
2025-07-16Whaley GlennBuy280.00K$0.77215.60K
2025-07-16Nash DuaneBuy630.00K$0.77485.10K
2025-07-16Nash DuaneBuy315.00K$0.77242.55K
2025-07-16Vitt DanielBuy1.72M$0.771.32M
2025-07-16Vitt DanielBuy860.00K$0.77662.20K
2025-07-16Muehler AndreasBuy660.00K$0.77508.20K
2025-07-16Muehler AndreasBuy330.00K$0.77254.10K
2025-07-16Tardio JasonBuy660.00K$0.77508.20K
2025-07-16Tardio JasonBuy330.00K$0.77254.10K
2025-06-13Nash DuaneBuy20.00K$0.8316.69K
2025-06-05Tardio JasonBuy598.50K$0.77462.58K
2025-06-05Whaley GlennBuy503.50K$0.77389.16K
2025-06-05Vitt DanielBuy1.56M$0.771.20M
2025-06-05Nash DuaneBuy570.00K$0.77440.55K
2025-06-05Muehler AndreasBuy598.50K$0.77462.58K
2025-06-05HOWSON TAMAR DBuy150.00K$0.77115.94K
2025-06-05Skerjanec SimonaBuy150.00K$0.77115.94K
2025-06-05Rudick Richard AlanBuy150.00K$0.77115.94K
2025-06-05Toernsen Monika MariaBuy150.00K$0.77115.94K
2025-06-05Tardio JasonBuy595.00K$0.77459.88K
2025-06-05Tardio JasonBuy12.51K$0.799.88K
2025-06-05Neermann JoergBuy150.00K$0.77115.94K
2025-06-05Whaley GlennBuy503.00K$0.77388.77K
2025-06-05Nash DuaneBuy560.00K$0.77432.82K
2025-06-05PHILLIPS BARCLAY ABuy150.00K$0.77115.94K
2025-06-05Muehler AndreasBuy595.00K$0.77459.88K
2025-06-05Vitt DanielBuy1.53M$0.771.19M
2025-06-05Neermann JoergBuy30.00K$0.7622.80K
2025-06-04Vitt DanielBuy15.00K$0.7711.55K
2025-06-04Neermann JoergBuy70.00K$0.7753.90K
2025-06-03Whaley GlennBuy45.00K$0.7132.08K
2025-06-03Rudick Richard AlanBuy143.07K$0.70100.02K
2025-05-30Whaley GlennBuy25.00K$0.5614.00K
2024-12-04Nash DuaneBuy300.00K$1.25375.00K
2024-12-04Muehler AndreasBuy315.00K$1.25393.75K
2024-12-04Tardio JasonBuy157.50K$1.25196.88K
2024-12-04Vitt DanielBuy820.00K$1.251.02M
2024-12-04Whaley GlennBuy265.00K$1.25331.25K
2024-11-12Rudick Richard AlanBuy87.30K$1.15100.37K
2024-07-22Skerjanec SimonaBuy100.00K$1.46146.00K
2024-07-22Skerjanec SimonaBuy50.00K$1.4673.00K
2024-07-22Skerjanec SimonaOther0——
2024-07-12Tardio JasonBuy500.00K$1.25625.00K
2024-07-12Tardio JasonOther0——
2024-06-11Neermann JoergBuy100.00K$1.27127.00K
2024-06-11PHILLIPS BARCLAY ABuy100.00K$1.27127.00K
2024-06-11Rudick Richard AlanBuy100.00K$1.27127.00K
2024-06-11Toernsen Monika MariaBuy100.00K$1.27127.00K
2024-06-11HOWSON TAMAR DBuy100.00K$1.27127.00K
2024-03-04HOWSON TAMAR DBuy64.96K$1.72111.73K
2024-03-04HOWSON TAMAR DSell15.00K$12.30184.50K
2024-03-04HOWSON TAMAR DSell9.99K$9.5495.27K
2024-03-04HOWSON TAMAR DSell10.00K$14.77147.70K
2024-03-04HOWSON TAMAR DSell10.00K$3.4034.00K
2024-03-04Nash DuaneBuy379.96K$1.72653.53K
2024-03-04Nash DuaneSell90.00K$15.441.39M
2024-03-04Nash DuaneSell19.97K$13.63272.23K
2024-03-04Nash DuaneSell120.00K$17.002.04M
2024-03-04Nash DuaneSell75.00K$10.88816.00K
2024-03-04Nash DuaneSell10.00K$3.4034.00K
2024-03-04Nash DuaneSell30.00K$12.30369.00K
2024-03-04Nash DuaneSell10.00K$14.77147.70K
2024-03-04PHILLIPS BARCLAY ABuy64.96K$1.72111.73K
2024-03-04PHILLIPS BARCLAY ASell15.00K$12.30184.50K
2024-03-04PHILLIPS BARCLAY ASell10.00K$3.4034.00K
2024-03-04PHILLIPS BARCLAY ASell9.99K$7.6376.19K
2024-03-04PHILLIPS BARCLAY ASell10.00K$14.77147.70K
2024-03-04Vitt DanielBuy485.00K$1.72834.20K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 61, holders -19 vs prior quarter. Ownership 282.06%.

HolderSharesChangeChange %Value
ABERDEEN GROUP PLC824.39K-7.42M-90.00%12.67M
BVF INC/IL765.29K-6.89M-90.00%11.76M
MILLENNIUM MANAGEMENT LLC740.35K-3.04M-80.41%11.38M
AVIDITY PARTNERS MANAGEMENT LP669.94K-6.03M-90.00%10.30M
BRAIDWELL LP645.01K645.01KNew9.91M
LAURION CAPITAL MANAGEMENT LP610.33K-3.27M-84.28%9.38M
VANGUARD CAPITAL MANAGEMENT LLC571.56K-4.57M-88.88%8.78M
JONES HILL CAPITAL LP539.81K539.81KNew8.30M
WOODLINE PARTNERS LP471.53K-495.62K-51.25%7.25M
SOLEUS CAPITAL MANAGEMENT, L.P.450.00K-4.05M-90.00%6.92M
PROPEL BIO MANAGEMENT, LLC325.02K-2.02M-86.14%5.00M
NANTAHALA CAPITAL MANAGEMENT, LLC250.65K-2.26M-90.00%3.85M
UBS GROUP AG175.76K-347.04K-66.38%2.70M
GEODE CAPITAL MANAGEMENT, LLC170.68K-1.36M-88.81%2.62M
683 CAPITAL MANAGEMENT, LLC147.25K-2.30M-93.99%2.26M
ADAGE CAPITAL PARTNERS GP, L.L.C.139.86K-1.26M-90.00%2.15M
BLACKROCK, INC.132.79K-831.44K-86.23%2.04M
SUSQUEHANNA INTERNATIONAL GROUP, LLP118.40K97.70K+471.98%1.82M
MARSHALL WACE, LLP104.82K104.82KNew1.61M
SUSQUEHANNA INTERNATIONAL GROUP, LLP90.89K70.19K+339.08%1.40M
JANE STREET GROUP, LLC89.69K74.59K+493.95%1.38M
JEFFERIES FINANCIAL GROUP INC.84.90K84.90KNew1.30M
VANGUARD FIDUCIARY TRUST CO82.03K-658.51K-88.92%1.26M
IKARIAN CAPITAL, LLC67.46K-607.20K-90.00%1.04M
STATE STREET CORP61.26K-504.39K-89.17%941.55K

Earnings and financials

Immunic, Inc. (IMUX) trades at $8.05, with a market cap of $109.88M and a trailing P/E of -1.54. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
6315.12000000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Immunic (IMUX) Financials: Revenue & Earnings

IMUX$8.05+0.44 +5.83%

$109.88M

Market Cap

-1.54

P/E

5.33

Forward P/E

—

Score

Price History